共查询到20条相似文献,搜索用时 0 毫秒
1.
Probiotic supplementation with Lactobacillus plantarum and Pediococcus acidilactici for Helicobacter pylori therapy: A randomized,double‐blind,placebo‐controlled trial 下载免费PDF全文
Adrian G. McNicholl Javier Molina‐Infante Alfredo J. Lucendo José Luis Calleja Ángeles Pérez‐Aisa Inés Modolell Xavier Aldeguer Margalida Calafat Luis Comino Mercedes Ramas Ángel Callejo Carlos Badiola Jordi Serra Javier P. Gisbert 《Helicobacter》2018,23(5)
2.
3.
4.
5.
Brief report: Lactobacillus bulgaricus GLB44 (Proviotic™) plus esomeprazole for Helicobacter pylori eradication: A pilot study 下载免费PDF全文
Background
Recent studies of Lactobacillus delbrueckii subsp. bulgaricus GLB44 plus a proton‐pump inhibitor (PPI) reported cures of more than 90% of patients with active Helicobacter pylori infections.Aim
To confirm the high H. pylori cure rates reported previously.Method
A pilot study was done in healthy H. pylori‐infected volunteers using 3‐gram sachet (3 billion cells) of L. delbrueckii GLB44 plus 22.3 mg of esomeprazole b.i.d., for 14 days. The result was determined by urea breath testing 4 weeks after therapy. Stopping rules required for ending enrollment if less than 3 of the first 10 subjects were cured.Results
Nine subjects were entered and because all failed to achieve negative urea breath test, the stopping rule required the study to end.Conclusion
We were unable to confirm reports of achieving a high H. pylori cure rate with L. delbrueckii GLB44 plus a PPI. 相似文献6.
Anti‐Helicobacter pylori Antibody Profiles in Epstein‐Barr virus (EBV)‐Positive and EBV‐Negative Gastric Cancer 下载免费PDF全文
M. Constanza Camargo Kyoung‐Mee Kim Keitaro Matsuo Javier Torres Linda M. Liao Douglas R. Morgan Angelika Michel Tim Waterboer Jovanny Zabaleta Ricardo L. Dominguez Yasushi Yatabe Sung Kim Erick R. Rocha‐Guevara Jolanta Lissowska Michael Pawlita Charles S. Rabkin 《Helicobacter》2016,21(2):153-157
7.
8.
Intracellular Osteopontin Induced by CagA‐positive Helicobacter pylori Promotes Beta‐catenin Accumulation and Interleukin‐8 Secretion in Gastric Epithelial cells 下载免费PDF全文
Wei‐Lun Chang Hsiao‐Bai Yang Hsiu‐Chi Cheng Yi‐Chun Yeh Cheng‐Yen Kao Jiunn‐Jong Wu Cheng‐Chan Lu Bor‐Shyang Sheu 《Helicobacter》2015,20(6):476-484
9.
10.
11.
Helicobacter pylori‐induced Sonic Hedgehog Expression is Regulated by NFκB Pathway Activation: The Use of a Novel In vitro Model to Study Epithelial Response to Infection 下载免费PDF全文
Michael A. Schumacher Rui Feng Eitaro Aihara Amy C. Engevik Marshall H. Montrose Karen M. Ottemann Yana Zavros 《Helicobacter》2015,20(1):19-28
12.
Editorial – Avoiding Unethical Helicobacter pylori Clinical Trials: Susceptibility‐Based Studies and Probiotics as Adjuvants 下载免费PDF全文
David Y. Graham 《Helicobacter》2015,20(5):321-325
As a general rule, any clinical study where the result is already known or when the investigator(s) compares an assigned treatment against another assigned treatment known to be ineffective in the study population (e.g., in a population with known clarithromycin resistance) is unethical. As susceptibility‐based therapy will always be superior to empiric therapy in any population with a prevalence of antimicrobial resistance >0%, any trial that randomizes susceptibility‐based therapy with empiric therapy would be unethical. The journal Helicobacter welcomes susceptibility or culture‐guided studies, studies of new therapies, and studies of adjuvants and probiotics. However, the journal will not accept for review any study we judge to be lacking clinical equipoise or which assign subjects to a treatment known to be ineffective, such as a susceptibility‐based clinical trial with an empiric therapy comparator. To assist authors, we provide examples and suggestions regarding trial design for comparative studies, for susceptibility‐based studies, and for studies testing adjuvants or probiotics. 相似文献
13.
14.
Superoxide dismutase from Helicobacter pylori suppresses the production of pro‐inflammatory cytokines during in vivo infection 下载免费PDF全文
Background
Helicobacter pylori has undergone considerable adaptation to allow chronic persistence within the gastric environment. While H. pylori‐associated diseases are driven by an excessive inflammation, severe gastritis is detrimental to colonization by this pathogen. Hence, H. pylori has developed strategies to minimize the severity of gastritis it triggers in its host. Superoxide dismutase (SOD) is well known for its role in protecting against oxidative attack; less recognized is its ability to inhibit immunity, shown for SOD from mammalian sources and those of some bacterial species. This study examined whether H. pylori SOD (HpSOD) has the ability to inhibit the host immune response to these bacteria.Materials and Methods
The ability of recombinant HpSOD to modify the response to LPS was measured using mouse macrophages. A monoclonal antibody against HpSOD was generated and injected into H. pylori‐infected mice.Results
Addition of HpSOD to cultures of mouse macrophages significantly inhibited the pro‐inflammatory cytokine response to LPS stimulation. A monoclonal antibody was generated that was specific for SOD from H. pylori. When injected into mice infected with H. pylori for 3 months, this antibody was readily detected in both sera and gastric tissues 5 days later. While treatment with anti‐HpSOD had no effect on H. pylori colonization at this time point, it significantly increased the levels of a range of pro‐inflammatory cytokines in the gastric tissues. This did not occur with antibodies against other antioxidant enzymes.Conclusions
SOD from H. pylori can inhibit the production of pro‐inflammatory cytokine during in vivo infection. 相似文献15.
16.
17.
18.
Prevalence and Risk Factors of Helicobacter pylori Infection in Saudi Children: A Three‐Year Prospective Controlled Study 下载免费PDF全文
Mohammed Hasosah Mohammed Satti Amir Shehzad Ashraf Alsahafi Ghassan Sukkar Abdullah Alzaben Areej Sunaid Abdullah Ahmed Sami AlThubiti Areej Mufti Kevan Jacobson 《Helicobacter》2015,20(1):56-63
19.
Helicobacter pylori (H. pylori) infection has been associated with gastric disorders. The situation of H. pylori infection in China—where a high prevalence of H. pylori infection, a high incidence of gastric cancer, and widespread resistance to clarithromycin, metronidazole, and levofloxacin exist—is quite different from that in Western countries. In order for Chinese clinicians to better manage H. pylori infection, a Chinese Study Group on H. pylori published four consensus reports regarding the management of H. pylori infection in China between 1999 and 2012. The eradication rate with standard triple therapy was <80% in most areas of China. Bismuth is available in China, and bismuth‐containing quadruple therapy has been shown to produce a high eradication rate; thus, bismuth quadruple therapy could be recommended both as an initial and as a rescue therapy in China. There is no advantage of sequential therapy over triple therapy in Chinese patients, but the efficacy of concomitant therapy must be studied further. This review introduces the epidemiology, diagnosis, indicators, and therapies for the eradication of H. pylori in China in recent years. 相似文献